Literature DB >> 7625648

Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.

C R Alving1.   

Abstract

Liposomes have been proposed as vehicles for vaccines against parasitic and viral illnesses. Experimental vaccines against malaria, HIV, hepatitis A, and influenza virus have been shown to be safe and highly immunogenic in several human trials. Analysis of the intracellular trafficking patterns of liposomal antigen reveals that after being phagocytosed by macrophages, liposomal antigen readily escapes from endosomes into the cytoplasm of the macrophages. It is proposed that liposomal peptide antigen can enter either the Golgi apparatus or the endoplasmic reticulum and thereby interact with MHC class II or class I molecules. The intracellular cytoplasmic trafficking patterns of liposomal antigens raise the possibility that liposomes may have utility in human vaccines for induction of either humoral immunity or cytotoxic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625648     DOI: 10.1111/j.1749-6632.1995.tb44447.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses.

Authors:  Saurabh Wadhwa; Anekant Jain; Jerold G Woodward; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2011-10-31       Impact factor: 5.571

2.  Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.

Authors:  J J Drabick; A K Bhattacharjee; D L Hoover; G E Siber; V E Morales; L D Young; S L Brown; A S Cross
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Authors:  L L Van De Verg; A B Hartman; A K Bhattacharjee; B D Tall; L Yuan; K Sasala; T L Hadfield; W D Zollinger; D L Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.

Authors:  Ali Badiee; Mahmoud R Jaafari; Afshin Samiei; Dina Soroush; Ali Khamesipour
Journal:  Clin Vaccine Immunol       Date:  2008-01-30

5.  Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Authors:  Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Julie Lovchik; Rick C Lyons; Carl R Alving; Venigalla B Rao; Mangala Rao
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

6.  Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice.

Authors:  Ahmad Mehravaran; Maryam Rezaei Nasab; Hadi Mirahmadi; Iraj Sharifi; Ebrahim Alijani; Amin Reza Nikpoor; Javad Akhtari; Mansure Hojatizade
Journal:  Iran J Basic Med Sci       Date:  2019-08       Impact factor: 2.699

7.  Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.

Authors:  Ensieh Golali; Mahmoud Reza Jaafari; Ali Khamesipour; Azam Abbasi; Zahra Saberi; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2012-09       Impact factor: 2.699

Review 8.  Nanotechnology in vaccine delivery.

Authors:  Laura J Peek; C Russell Middaugh; Cory Berkland
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.